BR112023023036A2 - Métodos de tratamento de distúrbios autoimunes usando proteínas de ligação a ilt7 - Google Patents

Métodos de tratamento de distúrbios autoimunes usando proteínas de ligação a ilt7

Info

Publication number
BR112023023036A2
BR112023023036A2 BR112023023036A BR112023023036A BR112023023036A2 BR 112023023036 A2 BR112023023036 A2 BR 112023023036A2 BR 112023023036 A BR112023023036 A BR 112023023036A BR 112023023036 A BR112023023036 A BR 112023023036A BR 112023023036 A2 BR112023023036 A2 BR 112023023036A2
Authority
BR
Brazil
Prior art keywords
methods
ilt7
binding proteins
autoimmune disorders
treatment
Prior art date
Application number
BR112023023036A
Other languages
English (en)
Portuguese (pt)
Inventor
Edward Hammond
Gabor Illei
John Ratchford
Jorn Drappa
Li Yan
William Rees
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of BR112023023036A2 publication Critical patent/BR112023023036A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR112023023036A 2021-05-04 2022-05-04 Métodos de tratamento de distúrbios autoimunes usando proteínas de ligação a ilt7 BR112023023036A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163183886P 2021-05-04 2021-05-04
US202163197789P 2021-06-07 2021-06-07
US202163242768P 2021-09-10 2021-09-10
US202163249953P 2021-09-29 2021-09-29
US202263326424P 2022-04-01 2022-04-01
PCT/US2022/027620 WO2022235758A1 (en) 2021-05-04 2022-05-04 Methods of treatment of autoimmune disorders using ilt7 binding proteins

Publications (1)

Publication Number Publication Date
BR112023023036A2 true BR112023023036A2 (pt) 2024-01-23

Family

ID=82021082

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023036A BR112023023036A2 (pt) 2021-05-04 2022-05-04 Métodos de tratamento de distúrbios autoimunes usando proteínas de ligação a ilt7

Country Status (10)

Country Link
US (1) US20240287176A1 (https=)
EP (1) EP4333877A1 (https=)
JP (1) JP2024516698A (https=)
KR (1) KR20240004451A (https=)
AU (1) AU2022270101A1 (https=)
BR (1) BR112023023036A2 (https=)
CA (1) CA3217278A1 (https=)
IL (1) IL308132A (https=)
MX (1) MX2023013015A (https=)
WO (1) WO2022235758A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
AR130042A1 (es) * 2022-07-27 2024-10-30 Viela Bio Inc Formulaciones que comprenden una proteína de unión al transcripto 7 similar a inmunoglobulina (ilt7)
EP4593823A1 (en) * 2022-09-30 2025-08-06 Abbvie Inc. Methods of treating hidradenitis suppurativa
WO2024126431A1 (en) * 2022-12-12 2024-06-20 Horizon Therapeutics Ireland Dac Anti-ilt7 binding agents for the treatment and prevention of myositis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ616992A (en) * 2005-12-20 2015-07-31 Sbi Biotech Co Ltd Anti-ilt7 antibody
US20110311558A1 (en) * 2008-12-01 2011-12-22 The Board Of Regents Of The University Of Texas System Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases
CA2772921A1 (en) * 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
IL293572A (en) 2019-12-06 2022-08-01 Viela Bio Inc Treatment methods using ilt7 binding proteins

Also Published As

Publication number Publication date
JP2024516698A (ja) 2024-04-16
WO2022235758A1 (en) 2022-11-10
MX2023013015A (es) 2023-11-15
EP4333877A1 (en) 2024-03-13
AU2022270101A1 (en) 2023-10-05
KR20240004451A (ko) 2024-01-11
US20240287176A1 (en) 2024-08-29
IL308132A (en) 2023-12-01
CA3217278A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
BR112023023036A2 (pt) Métodos de tratamento de distúrbios autoimunes usando proteínas de ligação a ilt7
BR112022010786A2 (pt) Métodos de tratamento usando proteínas de ligação a ilt7
Neumann et al. Induction of MHC class I genes in neurons
Vitale et al. Effect of tumor cells and tumor microenvironment on NK‐cell function
Klopstein et al. Beneficial effects of αB-crystallin in spinal cord contusion injury
Deng et al. miR-136-5p regulates the inflammatory response by targeting the IKKβ/NF-κB/A20 pathway after spinal cord injury
Oliveira-Fusaro et al. P2X4 receptors on muscle macrophages are required for development of hyperalgesia in an animal model of activity-induced muscle pain
Crawford et al. FcγRI mediates serum amyloid P inhibition of fibrocyte differentiation
Schneider et al. Muscle LIM protein: expressed in slow muscle and induced in fast muscle by enhanced contractile activity
JP2017518303A5 (https=)
Recabal et al. The FGF2‐induced tanycyte proliferation involves a connexin 43 hemichannel/purinergic‐dependent pathway
WO2019165097A1 (en) Universal antigen presenting cells and uses thereof
US20250313603A1 (en) Primary NK CAR Constructs And Methods
BR112022020639A2 (pt) Anticorpos anti-dectina-2
Li et al. M1‐Polarized Macrophages Promote Self‐Renewing Phenotype of Hepatic Progenitor Cells with Jagged1‐Notch Signalling Involved: Relevance in Primary Sclerosing Cholangitis
Dong et al. Involvement of EphB1 receptor/ephrinB1 ligand in bone cancer pain
Van Huysse et al. Hypertension from chronic central sodium chloride in mice is mediated by the ouabain-binding site on the Na, K-ATPase α2-isoform
Choi et al. Carbon monoxide reverses adipose tissue inflammation and insulin resistance upon loss of ovarian function
Masjkur et al. Neurovascular signals suggest a propagation mechanism for endogenous stem cell activation along blood vessels
CN116390736A (zh) 用于减轻化疗引起的毒性的内皮细胞
BR102020007149A8 (pt) Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
Bao et al. Transcriptome profiling of the subventricular zone and dentate gyrus in an animal model of Parkinson's disease
Heidegger et al. Virus-associated activation of innate immunity induces rapid disruption of Peyer’s patches in mice
MX2022005595A (es) Método para tratar o mejorar el síndrome de cushing usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr).
Xu et al. Suppressor of cytokine signaling 3 (SOCS3) gene transfer prolongs the survival of the murine cardiac allograft by attenuating interleukin‐17‐producing alloreactive T‐cell responses

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: VIELA BIO, INC. (US)